[Ip-health] Senator Angus King amendment to National Defense Authorization Act (NDAA) on federally funded drugs, vaccines

Kim Treanor kim.treanor at keionline.org
Wed Jul 5 08:17:27 PDT 2017


https://www.keionline.org/node/2823

Senator Angus King amendment to National Defense Authorization Act (NDAA)
on federally funded drugs, vaccines
James Love on 5. July 2017 - 9:08

Senator Angus King proposed an amendment to National Defense Authorization
Act (NDAA) that would require the Department of Defense (DoD) to authorize
third parties to use inventions that benefited from DoD research funding,
when prices exceed the median price charge in the seven largest economies
with per capita incomes at least half the per capita income in the United
States.

The amendment, which was approved by the Senate Armed Services Committee
but is not yet law, would effectively require Astellas, a Japanese firm, to
dramatically lower the price for the prostate drug Xtandi, saving Medicare
alone as much as a half billion per year, and require Sanofi to price the
Army licensed Zika vaccine at a lower price.
This is the Senator's press release from June 28.

FOR IMMEDIATE RELEASE
June 28, 2017
Contact: Kathleen Connery Dawe/Scott Ogden (202) 224-5344

King Announces Victories for Maine in Senate Defense Legislation
Bill authorizes funding for the construction of new military facilities in
Maine, advances shipbuilding priorities, and supports Maine jobs
WASHINGTON, D.C. – U.S. Senator Angus King (I-Maine) announced today the
Senate Armed Services Committee, of which he is a member, has approved the
2018 National Defense Authorization Act (NDAA) with a number of provisions
that he supported that will benefit Maine.

Senator King also secured several additional victories, including:

FIGHTING UNFAIR DRUG PRICES: Senator King successfully included an
amendment aimed at reducing drug prices of medicines and treatments that
benefitted from Department of Defense research. The provision directs the
DoD to authorize third parties to use inventions that benefited from
Department funding whenever the price of a drug, vaccine, or other medical
technology is higher in the U.S. than the median price charged in the seven
largest economies that have a per capita income at least half the per
capita income of the U.S.



More information about the Ip-health mailing list